Halozyme Therapeutics, Inc. $HALO Stock Position Lowered by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,690 shares of the biopharmaceutical company’s stock after selling 84,291 shares during the period. Cary Street Partners Financial LLC’s holdings in Halozyme Therapeutics were worth $1,517,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its stake in Halozyme Therapeutics by 13.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,049 shares of the biopharmaceutical company’s stock valued at $224,000 after acquiring an additional 364 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares during the period. Advisors Preferred LLC purchased a new position in Halozyme Therapeutics during the third quarter valued at approximately $1,526,000. Intrust Bank NA increased its stake in Halozyme Therapeutics by 42.5% in the 3rd quarter. Intrust Bank NA now owns 6,565 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 1,959 shares during the period. Finally, Stevens Capital Management LP increased its stake in Halozyme Therapeutics by 17.5% in the 3rd quarter. Stevens Capital Management LP now owns 5,309 shares of the biopharmaceutical company’s stock valued at $389,000 after buying an additional 792 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $69.53 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The company has a market cap of $8.21 billion, a P/E ratio of 27.92, a P/E/G ratio of 0.28 and a beta of 0.97. The business’s 50 day moving average is $72.62 and its two-hundred day moving average is $70.63. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm’s quarterly revenue was up 51.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Citizens Jmp upped their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.56.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $55,733,662.16. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 49,398 shares of company stock valued at $3,650,592. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.